Author: http://wealthcreation.club

http://wealthcreation.club—We are educating regular people about how to be able to make more money in a disciplined way

Turn Compounding Into Your Edge.

http://wealthcreation.clubLeave a comment

💎 Alpha Binwani Capital | Private Closed-End JV Fund

Turn compounding into your edge. At an illustrative 9% a year, $50,000 grows to about $99,628 in 8 years. That is 1.99x, and it comes from simple compounding math. It is not a fund result.

Minimum investment: $50,000 USD. 

Choose your tier:

• 🟣 $1M+ | 2 years: Targeted 0.5% monthly income plus 21% annually

• 🔴 $250K+ | 5 years: Targeted 0.5% monthly income plus 15% annually

• 🟡 $100K+ | 2 years: Targeted 0.5% monthly income plus 11% annually

• 🟠 Below $100K | 4 years: Targeted 9% annually

Engineered performance, not marketing.

📲 WhatsApp: bit.ly/Alpha-Binwani-Capital

🌐 Website: alphabinwanicapital.com

💼 LinkedIn: bit.ly/Alpha-Binwani-Capital-LinkedIn

📰 Free newsletter: bit.ly/FreeAlphaNewsletter

#PrivateEquity #HighNetWorth #WealthManagement #JointVenture #ClosedEndFund #AlternativeInvestments #Compounding #PassiveIncome #AlphaBinwaniCapital

UK Faces Highest 10-Year Borrowing Costs Since 1999 as Budget Risks Loom

http://wealthcreation.clubLeave a comment
‼️ 🇬🇧 The UK is poised to pay its highest 10-year borrowing cost since 1999 as investors demand greater compensation for persistent inflation and potential spending increases ahead of next month’s budget. The Debt Management Office will auction up to £4.25 billion of 4.875% bonds due July 2036 on Tuesday, after the same issue yielded an average 5.16% last month—the highest level in almost two decades.

Novo Nordisk Turns to China in $2.6 Billion Obesity-Drug Pipeline Bet

http://wealthcreation.clubLeave a comment
‼️ 🇩🇰 Novo Nordisk will pay up to $2.6 billion to license an experimental obesity pill from China’s Jiangsu Hengrui Pharmaceuticals, strengthening its early-stage pipeline as it looks beyond Ozempic and Wegovy. The deal includes a $300 million upfront payment for rights to develop, manufacture and market the drug worldwide excluding mainland China, Hong Kong, Macau and Taiwan, while Hengrui could receive additional milestone payments and sales-based royalties.